APGE SCHEDULE 13D/A: SEC filing
An amendment to a Schedule 13D was
Filed with the SEC on · accession 0001104659-26-105122
APGE filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Sep 3, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
An amendment to a Schedule 13D was filed regarding Apogee Therapeutics, Inc. The filing text provided contains only the EDGAR directory listing and no substantive details about the amendment.
Key details
✦ Ask GOAX AI about this filing — what it means for APGE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for APGE?
Click hereFrequently asked questions
What did APGE file with the SEC on Sep 3, 2026?
APGE filed a SCHEDULE 13D/A (SEC filing). An amendment to a Schedule 13D was filed regarding Apogee Therapeutics, Inc. The filing text provided contains only the EDGAR directory listing and no substantive details about the amendment.
How do I read a SCHEDULE 13D/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).
Other APGE SEC filings
- SCHEDULE 13D/A · SEC filingSep 8, 2026
- 8-K · AcquisitionSep 3, 2026
- 8-K · AcquisitionAug 11, 2026
- 8-K · SEC filingAug 10, 2026
- 10-Q · SEC filingAug 10, 2026
- 144 · Insider sale plannedJul 1, 2026
- 8-K · AcquisitionJun 22, 2026
- 144 · Insider sale plannedJun 22, 2026
- 144 · Insider sale plannedJun 22, 2026
- 8-K · Material agreementJun 22, 2026
Get alerts when APGE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days